Clinical Trials Logo

Muscular Dystrophy, Duchenne clinical trials

View clinical trials related to Muscular Dystrophy, Duchenne.

Filter by:

NCT ID: NCT05689164 Recruiting - Clinical trials for Duchenne Muscular Dystrophy

A Study to Understand the Long-term Safety and Effects of an Experimental Gene Therapy for Duchenne Muscular Dystrophy.

Start date: March 13, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to understand the safety and effects of an experimental gene therapy called fordadistrogene movaparvovec. We are seeking participants from previous Pfizer interventional studies. We will follow participants' experience in this study for 10 years after the end of their previous study. Participants will have 1 annual onsite visit and a few annual remote visits. The exact number of remote visits will be decided by their study doctor.

NCT ID: NCT05688072 Completed - Clinical trials for Muscular Dystrophy, Duchenne Type

Trunk Oriented Exercises Versus Whole-body Vibration for Duchenne Muscular Dystrophy

Start date: January 15, 2023
Phase: N/A
Study type: Interventional

The abdominal muscles play an important role in stabilizing the trunk and providing postural stability. Children with Duchene muscular dystrophy have weak muscles, which may impair postural adjustments. These postural adjustments are required for gait and dynamic balance during the daily living activities.

NCT ID: NCT05683379 Recruiting - Clinical trials for Duchenne Muscular Dystrophy

AFFINITY BEYOND: Anti-AAV8 Antibody Assessment Study of Boys With DMD

Start date: December 20, 2022
Phase:
Study type: Observational

This is an observational screening study to evaluate the prevalence of anti-adeno-associated serotype 8 (AAV8) antibodies in participants with Duchenne muscular dystrophy (DMD).

NCT ID: NCT05670730 Recruiting - Clinical trials for Duchenne Muscular Dystrophy

Study of AOC 1044 in Healthy Adult Volunteers and Participants With Duchenne Muscular Dystrophy (DMD) Mutations Amenable to Exon 44 Skipping

EXPLORE44
Start date: November 9, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

AOC 1044-CS1 (EXPLORE44) is a Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of single and multiple ascending doses of AOC 1044 in healthy adult volunteers and participants with DMD mutations amenable to exon 44 skipping. Part A is a single dose design with multiple cohorts (dose levels) in healthy adult volunteers. Part B is a multiple-ascending dose design with 3 cohorts (dose levels) in participants with Duchenne.

NCT ID: NCT05661071 Active, not recruiting - Clinical trials for Duchenne Muscular Dystrophy

Neuropsychological Profiles of Children With Duchenne Muscular Dystrophy and Its Effects on Motor Functions

Start date: May 11, 2022
Phase:
Study type: Observational

This study was planned to determine neuropsychological profiles of children with Duchenne Muscular Dystrophy and investigation of its effects on motor functions & compare to typically developed peers.

NCT ID: NCT05657938 Completed - Clinical trials for Duchenne Muscular Dystrophy

Evaluation of Home Based Assessments on Participants With DMD

Start date: October 13, 2022
Phase:
Study type: Observational

This study is designed to evaluate the feasibility, wearability and participant satisfaction of novel outcome assessment tools in DMD patients which are performed in the home environment.

NCT ID: NCT05641805 Recruiting - Clinical trials for Duchenne Muscular Dystrophy

Physical Activity Level and Cognitive Functions in Children With Duchenne Muscular Dystrophy

Start date: November 29, 2022
Phase:
Study type: Observational [Patient Registry]

Although there are studies showing that the effect on motor performance over time in children with DMD is associated with a decrease in the level of physical activity, no publication has been found that directly examines the relationship between cognitive functions and physical activity level. Therefore, the aim of our study is to investigate the relationship between physical activity level and cognitive functions in children with DMD.

NCT ID: NCT05601986 Recruiting - Clinical trials for Duchenne Muscular Dystrophy

Motor Imagery on Children With DMD on Gait and Balance Functions

Start date: December 16, 2022
Phase: N/A
Study type: Interventional

The most common muscular dystrophy among pediatric neuromuscular diseases is Duchenne Muscular Dystrophy (DMD). There is no consensus on a standardized physiotherapy and rehabilitation program or exercise prescription in DMD. Motor imagery (MI) is defined as visualizing motor activities in one's mind without performing any movement. There are studies examining the effectiveness of motor imagery in stroke, cerebral palsy, Parkinson's, peripheral facial paralysis, and phantom pain. This study is aimed to examine the effect of motor imagery on gait and balance functions in children with Duchenne Muscular Dystrophy. Boys residing in Istanbul Turkey, between the ages of 5 and 12, with a diagnosis of DMD who have not lost their ability to ambulate independently will be included in the study. The included individuals will be divided into two groups due to randomization: Group A (Control Group Physiotherapy and Rehabilitation Program) and Group B (Additional Motor Imagery Training to Intervention Group Physiotherapy and Rehabilitation Program). While the physiotherapy and rehabilitation program is applied to the participants in Group A with 40-minute sessions on 2 non-consecutive days of the week for 8 weeks, the participants in Group B will receive an additional 25-30-minute motor imagery program to the physiotherapy and rehabilitation program. Participants were tested with Kinovea Gait Analysis, Timed Up and Go Test, 2 Minute Walking Test, Motor Function Rating Scale for Neuromuscular Diseases, timed performance tests, Pediatric Berg Balance Scale, Pediatric Fear of Fall Questionnaire (Ped-FOF) before and after the program. will be evaluated later. IBM SPSS (Statistical Package for Social Sciences) statistical program version 22.0 will be used for statistical analysis. The conformity of the variables to the normal distribution will be determined by the "Shapiro-Wilk Test". If the variables show normal distribution, the variation within the group will be analyzed with the "Paired Sample T Test", if not, the "Wilcoxon Test" will be analyzed. In the comparison between groups, if the variables show normal distribution, it will be done with the "Independent T Test" in independent groups and the "Mann Whitney U Test" if they do not show normal distribution. Categorical data distributions will be evaluated with the "Chi-square test". In all analyses, p<0.05 will be considered statistically significant.

NCT ID: NCT05575648 Completed - Clinical trials for Duchenne Muscular Dystrophy

Dual Task in Duchenne Muscular Dystrophy

Start date: September 6, 2022
Phase: N/A
Study type: Interventional

This study was planned to determine the effects of the dual-task performance of children with DMD with motor dysfunction and varying degrees of cognitive impairment compared to their healthy peers, to compare the dual-task performance of children with different functional levels, and to determine the relationship between parameters that may affect dual-task performance.

NCT ID: NCT05564962 Completed - Clinical trials for Duchenne Muscular Dystrophy

Quality and Independence of Gait Classification Scale for DMD (QIGS-DMD)

Start date: January 19, 2021
Phase:
Study type: Observational

The aim of this study was to develop a reliable and valid gait classification scale for Duchenne Muscular Dystrophy (QIGS-DMD). The items of the QIGS-DMD were designed based on the literature review considering existing functional classification scales, gait scales, and the opinions of the physiotherapists who were expertized in rehabilitation of patients with DMD. Content validity was determined based on the opinions of a total of ten expert physiotherapists. Videos were recorded during gait of 69 children with DMD and inter- and intra-rater reliability were examined. Criterion validity was determined according to the relationship between QIGS-DMD and Motor Function Measure (MFM) and Vignos Lower Extremity Rating Scale (VLERS).